Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | Director | June 16, 2021 | June 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 16, 2021 · Filed June 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 7,800 |
Reported balance
After 2021-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-16 · Grant · Acquired 7,800 · Balance 7,800 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.53 · Expires 2031-06-15 | Direct | 17,498 |
Reported balance
After 2021-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-16 · Grant · Acquired 17,498 · Balance 17,498 F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.
F3: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2021 Filed Jun 21, 2021 16:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000119 · wf-form4_162430762887048.xml · derivative · entry 2 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000119 · wf-form4_162430762887048.xml · nonDerivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:18 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000079 · wf-form4_159259789928473.xml · derivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000056 · wf-form4_155993828045293.xml · derivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:47 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 63,290 | $0.00 Strike: $12.72 | $0.00 |
DisclosureSEC source: 0001179110-18-005403 · edgar.xml · derivative · entry 1 su Jingshyh S · CIK 0001315720 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,290 Underlying: Ordinary Shares · 63,290 shares Expires 2028-04-01 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in equal installments on the first, second and third anniversary of the grant date and shall become exercisable in full on the date of the third annual meeting of shareholders following the grant date. All vesting shall cease if the reporting person resigns from the board or otherwise ceases to serve as a director, unless the board determines that the circumstances warrant the continuation of vesting. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share ("ADS") represents 13 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.